ERCC1 and metastatic neoplasm: In another study on 32 women with recurrent or metastatic disease undergoing platinum-based chemotherapy, the patients with high ERCC1 expression experienced a lower response rate (15% versus 74%, p = 0.001), a shorter PFS (HR = 2.428; 95%CI =1.145–5.148), and a shorter OS (HR = 2.322; 95% CI = 1.051–5.29) compared to those with low ERCC1 expression [106].